Miriam F. Moffatt, D.Phil., Ivo G. Gut, Ph.D., Florence Demenais, M.D., David P. Strachan, M.D., Emmanuelle Bouzigon, M.D., Ph.D., Simon Heath, Ph.D., Erika von Mutius, M.D., Martin Farrall, F.R.C.Route., Tag Lathrop, Ph.D., and William O.C.M. Cookson, M.D., D.Phil. For the GABRIEL Consortium: A Large-Level, Consortium-Based Genomewide Association Research of Asthma Asthma is a syndrome of unknown origins that is characterized by inflamed and abnormal mucosa of the airways, wheezing, and shortness of breath. In a few patients, irreversible airway redecorating and intractable airflow limitation may develop. The disease has a high prevalence and a persistent relapsing course.However the discovery of the enzyme's 3D framework has allowed the researchers to pinpoint distinctive structural differences between the human being and the parasite's type of the enzyme. Subsequent drug targets can selectively block the parasite's enzyme, leaving the individual's intact.. Advaxis receives USPTO patent for Listeria vaccine The U.S. Trademark and Patent Workplace has approved Advaxis, Inc., , the live, attenuated Listeria monocytogenes immunotherapy firm, intellectual property safety to patent application 11/223,945 – a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu , when using the company’s proprietary listeriolysin O fusion system technology.